Effects of Different Early Intensive Therapies on Long-term β-cell Function

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 264 participants.

Also called NCT01471808

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 264 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01471808
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01471808. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2018-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Different Early Intensive Therapies on Long-term β-cell Function
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
CSII
Intervention (Drug)
CSII, Metformin, Pioglitazone
Intervention (Drug)
CSII, Sitagliptin
Lead sponsor
Sun Yat-sen University (class: other)
Collaborator
Nanfang Hospital, Southern Medical University (class: other)
Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (class: other)
Collaborator
Peking University Shenzhen Hospital (class: other)
Collaborator
First People's Hospital of Foshan (class: other)

Record details

Record id
cardio:ct-nct01471808
Content hash
8311dff1600aaea2d8b2d494d1a69c4d6566b6d39078928bedf605d5da728c4d